Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 + Bevacizumab in MSI-H/dMMR Colorectal Cancer
NCT07009145Phase 2Not yet recruiting
- Sponsor
- Shandong Provincial Qianfoshan Hospital
- Start
- Jun 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in colorectal cancer (CRC), sponsored by Shandong Provincial Qianfoshan Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07009145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07009145.